Figure S1. TFV (top) and TFV-DP (bottom) concentrations in the caudal rabbit vaginal tissue following a single dose of TFV tablet, intact or predissolved, or TFV 1% gel (10 mg TFV each). Data are median + SD (n = 5). Dashed line denotes the lower limit of quantitation (100 ng/g).
**Figure S2.** TFV iliac lymph node concentrations vagina following a single dose of TFV tablet, intact or predissolved, or TFV 1% gel (10 mg TFV each). Data are median + SD ($n = 5$). Dashed line denotes the lower limit of quantitation (20 ng/g).

**Figure S3.** TFV (top) and TFV-DP (bottom) concentrations in caudal vaginal tissues at 4 and 24 h following a single or 7 daily doses of intact TFV or TFV/FTC tablets. Data are median + SD ($n = 6$). Dashed line denotes the lower limit of quantitation (100 ng/g).
**Figure S4.** FTC concentrations in caudal vaginal tissues at 4 and 24 h following a single or 7 daily doses of intact FTC or TFV/FTC tablets. Data are median + SD ($n = 6$).

**Figure S5.** TFV concentrations in iliac lymph nodal tissues at 4 and 24 h following a single or 7 daily doses of intact TFV or TFV/FTC tablets. Data are median + SD ($n = 6$).

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).